ACROBiosystems/Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1/100ug/SAD

价格
¥50000.00
货号:SAD
浏览量:127
品牌:ACROBiosystems
服务
全国联保
正品保证
正规发票
签订合同
商品描述
  • Description
    Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 (SAD-S35) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 1.47 μg/mL using SARS-CoV-2 Inhibitor Screening Kit (Cat. No. EP-105). Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.
  • Isotype
    Human IgG1/kappa
  • Specificity
    This product is a specific neutralizing antibody against SARS-CoV-2 Spike Protein RBD domain and no cross-reactivity was detected against SARS-CoV Spike protein. The cross-reactivity with other coronaviruses has not been tested yet.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 . Normally trehalose is added as protectant before lyophilization.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. 4-8°C for 12 months in lyophilized state;
    2. -70°C for 3 years under sterile conditions after reconstitution.
Bioactivity-ELISA
Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) ELISA bioactivity

Serial dilutions of Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 (Cat.No. SAD-S35) was detected by SARS-CoV-2 Inhibitor screening Kit (Cat.No. EP-105) with a half maximal inhibitory concentration (IC50) of 1.472 μg/mL (QC tested).

Protocol
Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) ELISA bioactivity

Immobilized SARS-CoV-2 S1 protein, His Tag (Cat. No. S1N-C52H4) at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) with a linear range of 0.2-1.95 ng/mL (QC tested).

Protocol
Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) ELISA bioactivity

Determination of Anti-SARS-CoV-2 Neutralizing Antibody titer in different concentrations of human serum.Neutralizing titer of Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) measured by Anti-SARS-CoV-2 neutralizing antibody titer serologic assay kit (Cat. No. TAS-K003) in different concentrations of human serum (CV < 30%)="" (routinely="" tested).="">

Protocol
  • Background
    It"s been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

ACROBiosystems治疗性抗体的功效不仅取决于Fab片段及其与靶抗原的结合活性,还取决于Fc片段及其与关键Fc受体的相互作用。Fc片段对FcRn的结合亲和力(FCGRT&B2M)将预测抗体的半衰期,而Fc片段与FcγRIIIa(CD16a)之间的结合亲和力将影响抗体引发ADCC的能力(抗体依赖性细胞介导的细胞毒性)。因此,必须在抗体工程化过程中针对一组受体测试候选人。ACROBiosystems提供了完整的重组Fc受体蛋白集合,包括它们的常见变体,以帮助您加快mAb的开发。